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Abstract 
 
Objective: Insulin resistance has deleterious effects on cardiometabolic disease. We 
used Mendelian randomization analyses to clarify the causal relationships of insulin 
resistance on circulating blood-based metabolites to shed light on potential mediators 
of the insulin resistance to cardiometabolic disease relationship. 
 
Research Design and Methods: We used 53 single nucleotide polymorphisms 
associated with insulin resistance from a recent genome-wide association study to 
explore their effects on circulating lipids and metabolites. We used published 
summary-level data from two genome-wide association studies (GWASs) of 
European individuals; data on the exposure (insulin resistance) were obtained from 
meta-GWASs of 188,577 individuals and data on the outcomes (58 metabolic 
measures assessed by NMR) were taken from a GWAS of 24,925 individuals. 
 
Results: One standard deviation (SD) genetically elevated insulin resistance 
(equivalent to 55% higher geometric mean of fasting insulin, 0.89 mmol/L higher 
triglycerides and 0.46 mmol/L lower HDL-C) was associated with higher 
concentrations of all branched-chain amino acids, isoleucine (0.56 SD; 95%CI: 0.43, 
0.70), leucine (0.42 SD; 95%CI: 0.28, 0.55) and valine (0.26 SD; 95%CI: 0.12, 0.39) 
as well as with higher glycoprotein acetyls (an inflammation marker; 0.47 SD; 95%CI: 
0.32, 0.62) (P<0.0003 for each). Results were broadly consistent when using multiple 
sensitivity analyses to account for potential genetic pleiotropy. 
 
Conclusions: We provide robust evidence that insulin resistance causally impacts 
on each individual branched-chain amino acid and inflammation. Taken together with 
existing studies, this implies that branched-chain amino acid metabolism lies on a 
causal pathway from adiposity and insulin resistance to type 2 diabetes. 
 
 
Keywords: adiposity, insulin resistance, branched-chain amino acids, type 2 
diabetes 
 
Non-standard Abbreviations and Acronyms: BCAA, branched-chain amino acid; 
IR, insulin resistance; MR, Mendelian randomization; IVW, inverse variance 
weighted; GlycA, glycoprotein acetyls; BCKD, branched-chain α-ketoacid 
dehydrogenase. 
 
  
Page 19 of 53
CONFIDENTIAL−For Peer Review Only
Diabetes Care
 - 3 (16) - 
The obesity pandemic is a public health crisis leading to a dramatic surge in the 
incidence of type 2 diabetes mellitus (T2DM) and related diseases (e.g., 
cardiovascular diseases) (1). Adiposity, particularly visceral adiposity (2), is 
associated with insulin resistance (IR) and subsequent T2DM. Recent genetic 
studies employing the Mendelian randomization approach have shown adiposity 
traits (such as general adiposity, indexed by body mass index, and central adiposity, 
indexed by waist-to-hip ratio) to show causal relationships with blood pressure, lipids, 
coronary heart disease, stroke and diabetes (3-6). Furthermore, such studies have 
demonstrated that adiposity traits causally impact on insulin resistance (3,4,6). 
Insulin resistance is the clinical state of a reduced sensitivity to insulin, typically 
manifested as elevated levels of fasting insulin and often accompanied with higher 
levels of circulating triglycerides and lower levels of high-density lipoprotein 
cholesterol (HDL-C) (7).  
Exploring the molecular mechanism by which IR leads to T2DM may help to identify 
biomarkers that could mediate the relationship, and provide novel opportunities for 
disease prevention. Recent studies have suggested that branched-chain amino acids 
(BCAAs) might play a role in the development of T2DM. Prospective observational 
studies show that higher levels of circulating BCAAs are positively associated with 
markers of insulin resistance (8) and risk of incident T2DM (9,10). Recent genetic 
studies have also implicated the metabolism of BCAAs in the development of 
diabetes (11).  
Insulin resistance is a complex trait, which can be assessed by different metrics, 
including clamp/insulin suppression test (gold standard), insulin sensitivity test 
(based on OGTT), HOMA-IR and fasting insulin. The GENESIS consortium has 
published a GWAS of insulin sensitivity measured by clamp/insulin suppression test 
in a modest number of subjects (N = 5624) (12). However, the statistical power limits 
the findings of this study. Other metrics which can be more easily measured, such as 
fasting insulin or HOMA-IR, are often used in large-scale genetic and epidemiological 
studies. In the GWAS of fasting insulin conducted by Scott et al (up to 108,557 
individuals) (13), they also tested the associations of insulin-associated SNPs with 
lipid traits. They found that majority of the insulin-associated SNPs were associated 
with HDL-C and/or TG and this pattern was not observed for those SNPs associated 
with fasting glucose or 2hour glucose. Subsequently, a genetic instrument was built 
for insulin resistance that used the 19 SNPs associated with fasting insulin, and 
restricted the instrument to those SNPs that were also associated with triglycerides 
and HDL-C (14). This instrument was recently adopted by Mahendran et al, and the 
results suggest that insulin resistance might be causal for circulating concentrations 
of BCAAs (15). More recently, Lotta et al considerably expanded the set of SNPs 
associated with three components of insulin resistance (higher fasting insulin, higher 
triglycerides and lower HDL-cholesterol), identifying 53 such SNPs and found that the 
SNPs in aggregate also associated with risks of CHD and T2DM (7).  
Here we aim to: 1) assess the causal effects of insulin resistance employing these 53 
SNPs recently identified from across the genome that associated with higher fasting 
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insulin, higher triglycerides and lower HDL-C (7); 2) use multiple instruments and 
multiple sensitivity analysis as a means to detect and correct for potential genetic 
pleiotropy in order to ensure reliable findings; 3) expand the outcome measures from 
BCAAs to a comprehensive panel of amino acids (including alanine, glutamine, 
tyrosine and phenylalanine), lipoprotein subclasses, fatty acids, glycolysis-related 
measures and one inflammatory marker, which are established or emerging 
biomarkers for T2DM and cardiovascular diseases; 4) provide an overview of the 
potential causal pathways and mediator roles that insulin resistance places in the 
underlying association of adiposity with T2DM, by incorporating our findings into 
multiple strands of genetic evidence. 
 
Research Design and Methods 
We used published summary-level data from two GWA studies of European 
individuals (7,16). Data on the exposure (insulin resistance) were obtained from a 
meta-GWASs (meta-analysis of genome-wide association studies) of up to 188,577 
individuals (7) and data on the outcome (58 circulating metabolic measures) were 
taken from a GWAS of up to 24,925 individuals (16). Characteristics of these GWASs 
are reported in Supplemental Tables 1 & 2.  
 
Generation of Genetic Instruments 
We used the 53 SNPs associated with an insulin resistance phenotype from Lotta et 
al (7). In brief, Lotta et al. conducted a meta-GWAS to identify SNPs that associated 
with an insulin resistance phenotype of: (i) higher fasting insulin adjusted for BMI; (ii) 
higher triglycerides; and, (iii) lower HDL-C at P<0.005 for each trait. The combined 
association with the triad of phenotypes have been proposed as a means to 
characterising the genetic architecture of insulin resistance (7). This meta-GWAS 
identified 53 SNPs, of which a subset of 25 loci had been previously associated with 
triglycerides or HDL-C at genome-wide significance, whereas the remaining 28 had 
not. 
We used the 53 SNPs to generate a genetic instrument for IR. To conduct the 
Mendelian randomization (MR) analyses (17), we needed to obtain the association of 
SNPs with the exposure (insulin resistance) and also the associations with outcomes 
(metabolic measures). Lotta et al. (7) did not provide beta or SE for the associations 
of individual SNPs with the insulin resistance phenotype. To generate our own SNP 
to exposure estimate, we took the absolute value of the standardized beta coefficient 
for each of the 53 SNP associations with the individual components of the composite 
IR phenotype (i.e. fasting insulin adjusted for BMI, triglycerides and HDL-C) and 
meta-analysed the estimates together using a fixed-effect inverse-variance weighted 
method (data sources provided in Supplemental Table 3). We used this meta-
analysed value as the SNP-exposure estimate for the summary-level MR analyses. 
Supplemental Fig. 1 shows the associations of the 53 individual SNPs for our insulin 
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resistance trait with the three individual components. Most of the SNPs fell in a 
straight line (with a slope equal to 1), suggesting a similar contribution of the three 
traits to the ‘composite’ insulin resistance phenotype with the exception of rs1011685 
(near LPL), which had a much weaker effect on insulin adjusted for BMI. We 
therefore conducted sensitivity analyses in which rs1011685 was excluded from the 
instrument. 
 
Two-Sample Mendelian Randomization Analysis 
We used data from Kettunen et al. (16) to obtain SNP-associations with metabolic 
measures. Summary data for 58 measures were used in this study, including 14 
lipoprotein subclasses, 3 lipoprotein size measures, 9 total lipids, ApoA1, ApoB, 10 
fatty acids related measures, 9 amino acids, one inflammation marker - glycoprotein 
acetyls and several other measures. These metabolic measures were quantified by a 
high-throughput NMR metabolomics platform using primarily fasting serum samples 
with an approximately 1:1 male-to-female ratio and age span of 20-60 years 
(Supplemental Table 2). We used a conventional inverse variance weighted (IVW) 
MR analysis, in which the SNP to outcome estimate is regressed on the SNP to 
exposure, with the y-axis intercept forced through the origin. The data used for the 
MR analyses are presented in Supplemental Tables 3 & 4. 
 
Sensitivity Analyses 
As the conventional IVW MR approach can be vulnerable to unbalanced horizontal 
pleiotropy (18), we conducted MR-Egger, weighted median and weighted mode-
based MR analyses, which allow relaxation of some of the instrumental variable 
assumptions. The characteristics of these different MR methods are summarized in 
Supplemental Table 5. Overall, use of several MR methods that each makes different 
assumptions on the amount and type of genetic confounding is a useful strategy to 
assess the robustness of findings to potential violations of the instrumental variable 
assumptions (19).  
In addition to the 53 SNP instrument, we: (i) removed the rs1011685 (near LPL), 
which, as described above, did not show consistent associations across individual 
phenotypes of insulin resistance; (ii) used the 28 SNPs reported in Lotta et al. (7) that 
were not in loci previously associated with triglycerides or HDL-C at genome-wide 
significance, and (iii) used 12 SNPs associated with fasting insulin (BMI adjusted) 
reported by MAGIC consortium (13). As fasting insulin is another marker of insulin 
resistance, consistent results of the primary analysis and sensitivity analysis (iii) 
would provide further confidence in concluding the causal role of insulin resistance 
on the circulating metabolites. Further, sensitivity analysis (ii & iii) are helpful in 
assessing the contribution of primarily lipid-associated SNPs on the casual effect 
estimates. In addition, to quantify whether the genetic instruments for IR associated 
with BMI, we regressed the associations of SNPs with insulin resistance against the 
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associations of SNPs with BMI using summary-level data from GIANT consortium 
(20). A final step was to remove SNPs from the 53 SNP instrument that individually 
associated with BMI at P<0.001 using GIANT summary statistics (20) in order to 
clarify whether this materially altered the MR effect estimates. 
Genetic effect estimates are presented as standard deviation (SD) differences in 
metabolite concentrations per 1-SD genetically higher insulin resistance. To gain 
insight into the association of the genetic instrument with its individual components, 
we quantified the association of a 1-SD higher genetically higher insulin resistance 
on fasting insulin from the MAGIC consortium (13), and the blood lipids HDL-C and 
triglycerides from the Global Lipids Genetics Consortium (21). We used a two-sided 
P<0.001 (= 0.05/58; multiple testing correction) to denote evidence of an association. 
All analyses were conducted in R.  
 
Results 
The associations of the 53 SNPs with each of the metabolic measures are shown in 
Figure 1. As expected, all the SNPs associated with higher BMI-adjusted insulin and 
triglycerides and lower HDL-C. There were also general trends of the SNPs to 
associate with higher VLDL and lower HDL traits. 
Causal effect estimates of insulin resistance, proxied by the 53-SNP instrument, on 
the individual metabolic traits are illustrated in Figure 2. The association magnitudes 
(betas), standard errors and corresponding P-values are reported in Supplemental 
Table 6. A one-SD genetically higher insulin resistance was associated with 55% 
(95%CI: 50%, 60%) higher fasting insulin adjusted for BMI, 0.89 mmol/l (95%CI: 
0.85, 0.93) higher triglycerides and 0.46 mmol/l (95%CI: 0.44, 0.48) lower HDL-C. In 
addition, there were clear associations of the genetic instrument for insulin resistance 
with higher concentrations of all VLDL subclasses with more moderate associations 
with IDL and LDL subclasses. In contrast, the associations were inverse for most 
HDL subclasses. The genetic instrument was positively associated with VLDL and 
negatively with HDL particle size. These findings corroborate the characteristics of 
the instrument as devised by Lotta et al (7). Similarly, we identified positive 
associations of the genetic instrument with circulating fatty acids, including 
monounsaturated and omega-3 fatty acids. Interestingly, the genetic instrument only 
weakly associated with an increase in NMR-quantified glucose, a finding in keeping 
with the observation by Lotta et al. using the MAGIC consortium data (7). As reported 
in the original study (7), the genetic instruments were negatively associated with BMI 
(Supplemental Table 7). 
We identified strong positive associations of genetically higher insulin resistance with 
the BCAAs, isoleucine, leucine and valine. These estimates correspond to a 0.56 SD 
(95%CI: 0.43, 0.70) higher isoleucine, 0.42 SD (95%CI: 0.28, 0.55) higher leucine 
and 0.26 SD (95%CI: 0.12, 0.39) higher valine per 1-SD higher insulin resistance. 
Weaker associations were noticed with the other amino acids. In addition, genetically 
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higher insulin resistance was positively associated with glycoprotein acetyls, an 
inflammation marker (0.47 SD; 95%CI: 0.32, 0.62).  
 
Sensitivity Analyses 
Most of the associations identified for the 53-SNP instrument were replicated with the 
28-SNP instrument (limited to those SNPs that were not in loci of prior GWAS hits for 
triglycerides or HDL-C; Figure 2) as well as the 12-SNP instrument (identified in a 
GWAS of fasting insulin adjusted for BMI; Supplemental Fig. 2). The associations 
were also consistent when rs1011685 near LPL was removed from the 53-SNP 
instrument (Figure 2). Removal of 6 SNPs associated with BMI (P<0.001) had no 
material effect on the MR estimates (data not shown). 
To investigate the robustness of these MR estimates to potential confounding by 
genetic pleiotropy, we also investigated the association of the 53-SNP instrument 
with the BCAAs and glycoprotein acetyls (GlycA) using MR-Egger, weighted median 
and weighted mode-based estimators. Discordance of the point estimates was 
noticed across the methods, predominantly due to the inclusion of the rs1011685 
variant that had minimal effects on insulin adjusted for BMI (Supplemental Table 8). 
Since MR approaches can be vulnerable to the inclusion of such outliers, we 
repeated the sensitivity analyses excluding rs1011685, which led to estimates across 
all MR methods that were comparable to the IVW approach (Figure 3 and 
Supplemental Table 8). 
The intercepts of MR Egger were of generally small magnitude (absolute values ≤ 
0.01, far smaller than the corresponding beta coefficients) with little or no evidence 
that they departed from zero, providing little evidence for the presence of genetic 
pleiotropy (Supplemental Table 9). Because the MR-Egger estimate of the causal 
effect (obtained from the slope of the regression line) can be underestimated when 
the assumption of no measurement error of the exposure (NOME) is violated, the 
heterogeneity index (I2) was used to detect the extent of this potential violation (22). 
Results remained consistent when SIMEX-adjusted MR-Egger was used to correct 
potential errors of the SNP to exposure estimates (Supplemental Table 8). 
 
Pathways 
Figure 4 and Supplemental Table 10 illustrates the current evidence base for various 
pathways leading from adiposity to T2DM. Prior MR studies have shown that general 
adiposity (measured by BMI) and central adiposity (measured by waist-to-hip ratio 
adjusted for BMI) causally influence fasting insulin, HDL-C and triglycerides (4). BMI 
has been previously shown to influence BCAAs (23) and in this study we show that 
both BMI and waist-to-hip ratio (adjusted for BMI) impact these traits (Supplemental 
Fig. 3 & 4). Both BMI and waist-to-hip ratio causally affect diabetes (4). Our study 
shows that insulin resistance impacts on BCAAs, and together with a prior study 
providing genetic support of BCAAs metabolism in T2DM (11), the various sources of 
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data support a causal pathway that is from adiposity to insulin resistance to BCAAs 
to diabetes. 
 
Conclusions 
Our study provides genetic evidence in support of higher levels of insulin resistance 
leading to an elevation in circulating branched-chain amino acids. Within the context 
of other studies, our findings support the hypothesis that the metabolism of BCAAs 
may be a mediator that is downstream of adiposity and insulin resistance on the 
causal pathway to T2DM. If true, then this not only has important aetiological 
relevance, but also could point towards potential novel opportunities for disease 
treatment and prevention.  
These findings for insulin resistance and BCAAs are consistent with a recent paper 
by Mahendran et al. (15) in which ten IR associated SNPs were used to quantify the 
association with a composite measure of BCAAs in a one-sample MR setting of 
~1300 individuals. However, the selection of SNPs into the 10-SNP instrument may 
induce bias as the instrument was enriched for GWAS hits of fasting insulin that were 
also associated with triglycerides and HDL-C (18). In this study, a more robust 
approach was taken to instrument derivation by selecting >50 SNPs across the 
genome, which have recently been identified using a hypothesis-free approach to 
show directionally consistent associations with a triad of phenotypes that mark insulin 
resistance; this 53-SNP instrument was used to infer the causality of insulin 
resistance using a two-sample MR design with little overlap between datasets and 
with data on ~180,000 individuals for the SNP to exposure (IR) estimates and data 
on ~25,000 individuals for the SNP to outcome (metabolic markers) estimates. The 
consistent results that we report derived from multiple genetic instruments and 
multiple MR sensitivity analyses provide robust evidence that insulin resistance 
impacts on BCAAs in a cause and effect manner. Particularly, as insulin resistance 
can be measured by various metrics (e.g. a triad of the phenotypes as defined here 
and also by fasting insulin alone), the consistent results of the 53-SNP instrument (a 
genetic proxy for the insulin resistance triad) and 12-SNP instrument (a genetic proxy 
for fasting insulin alone) across the metabolic profile strengthens the evidence base 
for a causal role of insulin resistance and potentially validates the biological meaning 
of insulin resistance as defined by a complex phenotype characterised by higher 
insulin, higher triglycerides and lower HDL-C.  
Interventional studies provide orthogonal support for our findings that obesity and 
insulin resistance causally impact on circulating BCAAs. Multiple longitudinal studies 
have shown that BCAA levels were reduced after various insulin-sensitising 
interventions, including weight loss surgery through gastric bypass, pioglitazone 
therapy or physical exercise (24-26). Also, a reduction in BCAA concentrations was 
observed following the secretion of insulin during oral glucose tolerance test (OGTT), 
with individuals with insulin resistance showing less BCAA suppression (i.e. higher 
BCAA concentrations) following OGTT (27). Prospective studies have identified 
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circulating BCAAs to be predictive of incident T2DM and a recent genetic study found 
that the metabolism of BCAAs is likely causally linked to T2DM (11). Triangulating 
these sources of evidence provides support for the hypothesis that circulating BCAAs 
may mediate the relation from adiposity and insulin resistance to T2DM. On the other 
hand, observational studies have reported that higher dietary intake of BCAAs is 
associated with an improved cardiometabolic risk profile including a lower risk of 
T2DM (28,29). However, dietary BCAAs, both measured in absolute terms or as a 
percentage of total protein, are only weakly correlated with circulating concentrations 
of BCAAs (28,29). There is also evidence that the expression of enzymes involved in 
BCAA catabolism (e.g. branched-chain α-ketoacid dehydrogenase, BCKD) is 
reduced in obese and diabetic individuals (11,30). BCKD is responsible for the rate-
limiting step of BCAA catabolism and BCKD can be activated by its regulatory 
phosphatase encoded by PPM1K. Individuals with T2DM have reduced up-regulation 
of PPM1K in skeletal muscle during OGTT (11). Consistent with this, after weight 
loss surgery, BCKD concentrations are increased leading to a commensurate 
reduction in BCAAs (24,30). Thus, elevated circulating BCAA levels observed in 
obese and diabetic individuals could arise from impaired BCAA catabolism (11). 
Putting these strands of evidence together, it is plausible that pharmacotherapies to 
improve or restore the function of BCAA catabolism may represent a means to 
prevent T2DM. However, further studies are required to understand the exact role of 
BCAA metabolism in the aetiology of T2DM. 
In contrast to the strong effects of IR on the BCAAs, we noticed a generally weaker 
effect of IR on alanine, glutamine, and aromatic amino acids (phenylalanine and 
tyrosine). Each of these biomarkers has been associated with the risk of insulin 
resistance, hyperglycaemia, type 2 diabetes and cardiovascular diseases (8,10,31). 
Although imprecise estimates were observed for these measures in the MR analyses 
reported herein, the consistent results from different instruments on these traits 
merits further investigation in larger datasets to clarify whether these represent 
causal relationships. 
The association that we identify of insulin resistance with GlycA is novel. GlycA is a 
marker of both acute phase and chronic inflammation and has been linked to 
neutrophil activity (32). GlycA reflects circulating levels of various inflammatory 
glycoproteins (primarily alpha-1-acid glycoprotein and haptoglobin), and is also 
associated with a wide range of inflammatory cytokines (32). Prospective 
observational studies have identified positive associations of GlycA with 
cardiovascular disease, T2DM and premature mortality (33,34). A role for 
inflammation in the development of T2DM has been proposed for many years on 
account of the observational associations between higher concentrations of 
biomarkers of inflammation, such as C-reactive protein, interleukin-1, interleukin-6, 
and the risk of T2DM (35,36). Although recent MR studies have so far failed to 
provide evidence in support of this hypothesis (36), it remains plausible that such 
causal pathways (from inflammation to T2DM) exist, and that larger studies and/or 
investigations of other inflammatory markers and pathways may identify a causal role 
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of inflammation in T2DM. Therefore, GlycA could represent a biomarker either 
involved in, or correlated to an inflammation pathway involved in the aetiology of 
T2DM. A causal role of inflammation in vascular disease is gaining traction given 
recent findings from genetic studies in humans of the interleukin-6 receptor and CHD 
(37), and more recently in phase III clinical trials of anti-inflammatory drugs for the 
treatment of CHD (CANTOS trial of canakinumab, a monoclonal antibody to 
interleukin-1 beta) (38). Of note, a previous study has suggested that BMI has a 
causal impact on circulating concentrations of GlycA (23) (as we also report in 
Supplemental Fig. 3 for BMI and Fig.4 for WHR) and our study here provides 
clarification on the potential causal pathway, showing that insulin resistance is also 
causal for GlycA. However, elucidating the causal role of GlycA in cardiometabolic 
disease remains challenging using an MR approach since at present the identified 
genetic variants associated with GlycA are limited in number (16), thus hindering our 
ability to answer this important question. Larger GWAS of GlycA may facilitate this 
endeavor. 
Strengths of this study include: (i) a comprehensive genetic instrument for an insulin 
resistance phenotype using findings from a recent GWAS (7); (ii) characterizing and 
validating the genetic instrument for IR with a repertoire of biomarkers of triglyceride 
and HDL-C metabolism; (iii) use of multiple sensitivity analyses (both in the derivation 
of the genetic instruments and their application to state of the art MR methodologies) 
which provided robust and consistent evidence; (iv) quantifying the causal effects of 
insulin resistance on each of the three BCAAs individually; (iv) adding important new 
information on the effect of insulin resistance on an inflammation marker; and, (v) a 
data summation that provides evidence of a causal pathway from adiposity through 
IR and BCAA to T2DM. 
Limitations include: (i) analyses were conducted at the summary level and we could 
not investigate associations by subgroups, e.g., of age or sex, meaning that it is not 
possible to test whether these associations are modified by age; (ii) our analyses 
were conducted using European datasets which may hamper their translational 
relevance to non-Europeans, however risk factors for disease tend to show similar 
relationships across geographical regions (39) and emerging studies are providing 
evidence that shows the genetic architecture for common diseases is likely similar 
across ethnic groups (40) (iii) a meta-GWAS of 3 traits was used to proxy IR, which 
may not include other traits related to IR and may have limited clinical relevance, 
although in the original paper by Lotta et al. (7), associations were identified for 
diabetes and heart disease; (iv) meta-GWAS may select SNPs on the basis of 
pleiotropy (i.e., by their very selection, they associate with higher fasting insulin, 
higher triglycerides and lower HDL-C) and thus SNPs may tag heterogeneous 
pathways, some of which may result in unbalanced horizontal pleiotropy (18). Against 
this are the consistent associations across the different genetic instruments, their 
stability to various MR sensitivity analyses (with each MR approach having its own 
assumptions on the amount and type of genetic pleiotropy, see Supplemental Table 
5), and the general consistency with a prior study that used a weaker instrument in a 
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much smaller dataset (15). Finally, the instruments were derived from a meta-GWAS 
that included fasting insulin adjusted for BMI; conditioning on a trait in discovery 
GWAS can induce collider bias, as evidenced by the negative association of the 
instruments with BMI. However, this negative association with BMI would be 
expected to diminish the association of the genetic instruments with BCAA that we 
report (and also diminish the association with T2DM and CHD reported by Lotta et al. 
(7) rather than augment it, and therefore is unlikely to result in major bias in the MR 
estimates we report. Further, removal of six SNPs that were associated with BMI (at 
P<0.001 using GIANT summary statistics) had no material impact on the causal 
estimates derived from MR. 
In conclusion, our findings provide new information in support of a causal role of 
insulin resistance on branched chain amino acids and inflammation. Taken together 
with recent findings from complimentary studies, these data suggest BCAA 
metabolism may lie on a causal pathway from adiposity and insulin resistance to type 
2 diabetes. 
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Figure Legends 
 
Figure 1. Heat map of the 53 SNPs and their associations with 58 circulating 
biomarkers. The units are reported as an SD-difference in metabolic measure per 
insulin resistance increasing allele. Abbreviations: VLDL, very-low-density lipoprotein; 
IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; lipoprotein measures without further specification refer to total lipid 
concentrations; apoA1, apolipoprotein A-I; apoB, apolipoprotein B; w79s FA, omega 
7, 9 and saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids; DHA, docosahexaenoic acid; DBinFA, the average 
number of double bonds in fatty acids; FALen, the average fatty acid chain length. 
Insulin resistance was defined as a triad of higher fasting insulin (BMI adjusted), 
higher triglycerides and lower HDL-C. Metabolic measures were quantified by the 
high-throughput NMR metabolomics platform using primarily fasting serum samples. 
 
 
Figure 2. Forrest plot of the causal effect estimates of insulin resistance on 
circulating metabolic measures. Estimates are derived from inverse variance 
weighted (IVW) Mendelian randomization analyses. The three instruments are: 53 
SNPs identified from Lotta et al. (7) (black diamonds); 52 SNPs removing an outlier 
variant rs1011685 (near LPL) (red circles); 28 SNPs in loci not previously associated 
with high-density lipoprotein cholesterol and triglycerides at genome-wide 
significance (blue circles). Open and close symbols indicate P ≥ 0.001 and P < 0.001, 
respectively. Units are given as SD difference in metabolic measures per 1-SD 
genetically higher insulin resistance. Abbreviations are as listed in the caption for 
Figure 1. 
 
 
Figure 3. Funnel plots for the three branched-chain amino acids and 
glycoprotein acetyls showing the causal effect estimates. IVW refers to the 
conventional inverse variance weighted method (using 53 SNPs; red vertical lines), 
Egger to the MR-Egger (using 52 SNPs; green lines), WME to the weighted median 
estimator (using 52 SNPs; blue lines) and WMBE for the weighted mode-based 
estimator (using 52 SNPs; purple line). For the results shown for MR-Egger, WME 
and WMBE, the outlier SNP rs1011685 near LPL was removed. The 95% CIs for 
each method are shown as the colourful horizontal lines. Each individual black circle 
describes the causal effect estimate using the individual SNP as the instrument.  
 
 
Figure 4. Strands of evidence from multiple genetic studies supporting a 
causal pathway from adiposity, through insulin resistance and branched-chain 
amino acids, to diabetes. Sources of evidence: 1. Holmes et al. (3), Dale et al. (4); 
2. Dale et al. (4),  Emdin et al. (6); 3. Würtz et al. (23), this study (Supplemental Fig. 
3); 4. This study (Supplemental Fig. 4); 5. Holmes et al. (3), Dale et al. (4), Lyall et al. 
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(5); 6. Emdin et al. (6), Dale et al. (4); 7. This study (Figure 2), Mahendran et al. (15); 
8. Lotta et al. (11). For details of these studies and the MR estimates provided, 
please see Supplemental Table 10. *refers to adjustment with BMI.  
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Supplemental Table 1. Characteristics of the GWASs studies used in this study. 
Characteristics Exposure GWAS* (insulin resistance) Outcome GWAS 
Phenotype 
Fasting insulin adjusted for 
BMI 
Triglycerides and HDL 
cholesterol 
Circulating metabolic 
measures profiled by high-
throughput quantitative serum 
NMR metabolomics  
Consortium MAGIC GLGC MAGNETIC 
PubMed ID 22885924, 22581228 24097068 27005778 
N Up to 108,557 participants Up to 188,577 participants Up to 24,925 participants 
Ethnicity European European European 
Genotype data 
GWAS array and 
metabochip array 
GWAS array and 
metabochip array GWAS array 
*: Lotta et al (1) built a genetic instrument for insulin resistance by combining published GWAS results 
for fasting insulin (adjusted for BMI), HDL cholesterol and triglycerides. Here, the characteristics of the 
GWAS for each individual phenotype of insulin resistance are listed. 
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Supplemental Table 2. Characteristics of the individual cohorts used in the 
metabolite-GWAS. 
Study  Age BMI Female% 
 N Mean s.d. Mean s.d.  
EGCUT 3,287 46.3 19.5 26.4 5.4 58 
ERF 2,118 48.2 14.7 26.7 4.7 58 
FTC 664 23.9 2.1 23.1 3.7 50 
FR97 3,661 45.3 12.8 26.3 4.5 55 
COROGENE 828 53.2 13.2 26.6 4.1 54 
GenMets 572 55.8 7.3 27.2 4.5 57 
HBCS 708 61.3 2.9 27.1 4.1 60 
KORA 1,745 60.9 8.8 28.2 4.8 52 
LLS 2,227 59.2 6.8 25.4 3.5 54 
NTR 1,192 38.8 12.8 24.6 4.2 64 
NFBC 1966 4,709 31.2 0.4 24.6 4.1 51 
PredictCVD 374 47.5 14.6 26.6 4.4 37 
PROTE 597 38.3 16 25.2 4.6 51 
YFS 2,390 37.7 5 26 4.7 54 
 
 
Supplemental Table 3 and 4 presented as Excel files due to their large size. 
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Supplemental Table 5. Characteristics of different MR methods*. 
Method Principle Breakdown level †  
Stability to presence of 
horizontal pleiotropy 
Analytical code 
for the methods 
IVW (2) 
Combing the ratio estimates 
from individual SNPs via fixed-
effect meta-analysis; 
alternatively, interpreted as the 
regression of  SNP-outcome 
onto SNP-exposure forced 
through original. 
0% 
Stable if the sum of horizontal 
pleiotropic effects across all 
variants is zero. R and Stata 
codes for IVW 
and MR-Egger 
regression 
methods are 
available at Web 
Appendix of 
reference (3) 
MR-Egger 
regression ‡ 
(3) 
The regression of  SNP-outcome 
onto SNP-exposure allows the y-
intercept to float. The y-intercept 
is used to infer the presence and 
extent of unbalanced horizontal 
pleiotropy and the slope 
indicates the corrected causal 
effect estimate. 
100% 
Stable even if all variants are 
invalid provided that the 
associations of individual 
variants with the exposure are 
unrelated to the 
corresponding pleiotropic 
effects. 
Weighted 
median 
estimator (4) 
The median of the ratio 
estimates obtained from 
individual SNPs 
50% 
Stable if more than 50% of the 
weights is contributed by valid 
variants, regardless of the 
type of horizontal pleiotropy. 
R code is 
provided in 
Supporting 
Information 
Appendix 2 
from reference (4) 
Weighted 
mode-based 
estimator (5) 
The highest density of the ratio 
estimates across all SNPs 
Depends on 
the weights 
of individual 
SNP 
 
Stable if the largest number of 
similar individual-instrument 
causal effect estimates arise 
from valid instruments, 
regardless of the type of 
horizontal pleiotropy 
R code is 
provided in 
supplementary 
materials from 
reference (5) 
* This table is based on multiple previous publications (3-5).  
† Breakdown refers to the proportion of information that can come from invalid instrumental 
variables before the method gives biased estimates. 
‡ The MR-Egger estimate of the causal effect can be prone to be underestimated when the 
assumption of no-measurement error (NOME) of the SNP to exposure is violated; the 
heterogeneity index (I2) was used to detect the extent of the violation and MR-Egger with 
SIMEX was used to correct such violation (6).  
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Supplemental Table 6. The causal effect estimates using 53-SNP, 52-SNP and 28-SNP 
instrument via inverse-variance weighted method as shown in Figure 2. 
Metabolites 53-SNP instrument 52-SNP instrument 28-SNP instrument 
 Beta SE Pvalue Beta SE Pvalue Beta SE Pvalue 
Extremely large VLDL 0.67 0.08 4E-12 0.63 0.09 1E-09 0.64 0.10 1E-04 
Very large VLDL 0.72 0.07 4E-13 0.67 0.08 3E-10 0.67 0.10 7E-05 
Large VLDL 0.90 0.08 2E-16 0.81 0.09 8E-13 0.84 0.10 3E-06 
Medium VLDL 1.06 0.07 P<2E-16 0.93 0.08 5E-15 0.90 0.10 1E-06 
Small VLDL 0.96 0.07 P<2E-16 0.82 0.08 4E-13 0.74 0.10 2E-05 
Very small VLDL 0.59 0.07 2E-10 0.50 0.09 4E-07 0.41 0.10 9E-03 
IDL 0.24 0.07 2E-03 0.20 0.08 2E-02 0.22 0.10 1E-01 
Large LDL 0.23 0.07 4E-03 0.19 0.08 3E-02 0.27 0.10 7E-02 
Medium LDL 0.30 0.07 2E-04 0.25 0.08 6E-03 0.35 0.10 2E-02 
Small LDL 0.37 0.07 8E-06 0.32 0.08 4E-04 0.44 0.10 5E-03 
Very large HDL -0.64 0.08 2E-11 -0.58 0.09 1E-08 -0.35 0.10 2E-02 
Large HDL -0.96 0.07 P<2E-16 -0.90 0.08 2E-14 -0.63 0.10 2E-04 
Medium HDL -0.43 0.07 5E-07 -0.43 0.08 7E-06 -0.07 0.10 6E-01 
Small HDL 0.11 0.08 2E-01 0.06 0.09 5E-01 0.41 0.10 8E-03 
HDL C -0.98 0.07 P<2E-16 -0.92 0.08 2E-15 -0.50 0.10 1E-03 
ApoA1 -0.51 0.08 2E-08 -0.46 0.09 3E-06 -0.13 0.10 4E-01 
LDL C 0.21 0.07 5E-03 0.18 0.08 3E-02 0.32 0.10 3E-02 
Esterified C 0.10 0.09 2E-01 0.05 0.10 6E-01 0.31 0.20 8E-02 
Free C -0.05 0.09 5E-01 -0.07 0.10 5E-01 0.16 0.20 4E-01 
Total C 0.20 0.07 8E-03 0.14 0.08 9E-02 0.37 0.10 1E-02 
Total TG 1.03 0.07 P<2E-16 0.92 0.08 2E-15 0.92 0.10 3E-07 
ApoB 0.63 0.07 1E-11 0.57 0.08 1E-08 0.66 0.10 6E-05 
Phosphoglycerides 0.07 0.09 4E-01 0.01 0.10 9E-01 0.27 0.20 1E-01 
Cholines -0.07 0.09 4E-01 -0.12 0.10 2E-01 0.13 0.20 4E-01 
Sphingomyelin -0.24 0.09 9E-03 -0.27 0.10 9E-03 -0.18 0.20 3E-01 
VLDL particle size 0.94 0.07 P<2E-16 0.85 0.08 1E-13 0.83 0.10 3E-06 
LDL particle size -0.13 0.07 9E-02 -0.13 0.08 1E-01 -0.35 0.10 2E-02 
HDL particle size -0.88 0.08 4E-16 -0.80 0.09 1E-12 -0.61 0.10 2E-04 
Total FA 0.55 0.09 1E-07 0.42 0.10 1E-04 0.61 0.20 1E-03 
w79S FA 0.59 0.09 2E-08 0.47 0.10 3E-05 0.63 0.20 1E-03 
MUFA 0.56 0.09 5E-08 0.42 0.10 1E-04 0.61 0.20 1E-03 
Omega-3 FA 0.42 0.09 2E-05 0.37 0.10 7E-04 0.45 0.20 1E-02 
DHA 0.15 0.09 9E-02 0.13 0.10 2E-01 0.12 0.20 5E-01 
Omega-6 FA 0.31 0.09 1E-03 0.19 0.10 6E-02 0.36 0.20 5E-02 
Linoleic acid 0.29 0.09 2E-03 0.16 0.10 1E-01 0.36 0.20 4E-02 
other PUFA 0.28 0.09 3E-03 0.24 0.10 2E-02 0.23 0.20 2E-01 
DBinFA -0.37 0.08 5E-05 -0.33 0.10 1E-03 -0.38 0.20 3E-02 
FALen -0.66 0.09 1E-09 -0.57 0.10 9E-07 -0.66 0.20 6E-04 
Alanine 0.19 0.07 7E-03 0.23 0.08 4E-03 0.32 0.10 2E-02 
Glutamine -0.20 0.07 6E-03 -0.29 0.08 6E-04 -0.39 0.10 6E-03 
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Glycine -0.17 0.08 4E-02 -0.25 0.09 6E-03 -0.34 0.10 3E-02 
Histidine 0.19 0.07 2E-02 0.22 0.08 1E-02 0.17 0.10 2E-01 
Isoleucine 0.56 0.07 3E-11 0.65 0.08 4E-11 0.74 0.10 4E-06 
Leucine 0.42 0.07 9E-08 0.52 0.08 1E-08 0.65 0.10 3E-05 
Valine 0.26 0.07 3E-04 0.41 0.08 2E-06 0.49 0.10 7E-04 
Phenylalanine 0.12 0.07 1E-01 0.11 0.08 2E-01 0.28 0.10 4E-02 
Tyrosine 0.14 0.07 4E-02 0.19 0.08 2E-02 0.34 0.10 1E-02 
Glucose 0.15 0.07 3E-02 0.10 0.08 2E-01 0.00 0.10 1E+00 
Lactate 0.12 0.07 8E-02 0.13 0.08 1E-01 0.16 0.10 2E-01 
Pyruvate 0.20 0.07 5E-03 0.21 0.08 9E-03 0.26 0.10 5E-02 
Citrate -0.25 0.07 6E-04 -0.31 0.08 2E-04 -0.33 0.10 2E-02 
Glycerol 0.01 0.07 8E-01 -0.11 0.09 2E-01 -0.11 0.10 5E-01 
Acetate -0.16 0.07 3E-02 -0.20 0.08 1E-02 -0.18 0.10 2E-01 
Acetoacetate -0.15 0.08 5E-02 -0.28 0.09 2E-03 0.17 0.10 2E-01 
Beta-hydroxybutyrate -0.30 0.07 9E-05 -0.39 0.08 1E-05 -0.20 0.10 1E-01 
Creatinine -0.03 0.07 7E-01 -0.04 0.08 6E-01 -0.02 0.10 9E-01 
Albumin 0.06 0.08 4E-01 0.04 0.09 6E-01 0.23 0.10 1E-01 
Glycoprotein acetyls 0.47 0.07 5E-08 0.36 0.08 8E-05 0.25 0.10 9E-02 
 
The three instruments are: 53 SNPs identified from Lotta et al. (1); 52 SNPs removing an outlier 
variant rs1011685 (near LPL); 28 SNPs not previously associated with high-density lipoprotein 
cholesterol and triglycerides at genome-wide significance. The unit for Betas is reported as: SD 
metabolite per 1-SD higher insulin resistance. Insulin resistance is defined as a triad of higher fasting 
insulin (BMI adjusted), higher triglycerides and lower HDL cholesterol. 
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Supplemental Table 7. Associations of insulin resistance genetic instrument with 
body mass index. 
Instrument Estimate Std. Error CI 2.50% CI 97.50% Pvalue 
Association of insulin resistance genetic instrument with BMI (SD BMI per SD insulin resistance) 
53 SNPs 
-0.11 0.022 -0.16 -0.07 3.15E-06 
52 SNPs 
-0.16 0.025 -0.21 -0.11 4.29E-08 
28 SNPs 
-0.12 0.042 -0.21 -0.04 6.86E-03 
Association of fasting insulin (BMI adjusted) genetic instrument with BMI (SD BMI per SD insulin) 
12 SNPs 
-0.33 0.035 -0.41 -0.26 1.35E-06 
 
Two-sample MR via inverse variance weighted method was used to assess the causal effect 
estimates of insulin resistance (and fasting insulin) on body mass index (BMI). The associations of the 
instrument SNPs with BMI were obtained from GIANT consortium for up to 339,224 individuals (7). 
The four instruments are: 53 SNPs identified from Lotta et al. (1); 52 SNPs removing an outlier variant 
rs1011685 (near LPL); 28 SNPs not previously associated with high-density lipoprotein cholesterol 
and triglycerides at genome-wide significance; 12 SNPs associated with fasting insulin adjusted for 
BMI reported by MAGIC consortium (8).  
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Supplemental Table 8. Sensitivity analyses using different methods across all 
instruments. 
 Isoleucine 
Beta (95%CI); 
Pvalue 
Leucine 
Beta (95%CI); 
Pvalue 
Valine 
Beta (95%CI); 
Pvalue 
GlycA 
Beta (95%CI);  
Pvalue 
53 SNPs 
IVW 0.56 (0.43, 0.70) 
p=3e-11 
0.42 (0.28, 0.55) 
p=9e-08 
0.26 (0.12, 0.39) 
p=3e-04 
0.47 (0.32, 0.62) 
p=5e-08 
MR-Egger     
 Standard 
approach 
0.32 (0.07, 0.58) 
p=1e-02 
I2=0.95 
0.10 (-0.17, 0.37) 
p=5e-01 
I2=0.95 
-0.17 (-0.44, 0.10) 
p=2e-01 
I2=0.95 
0.63 (0.34, 0.92) 
p=3e-05 
I2=0.95 
 SIMEX 
adjusted 
0.34 (0.02, 0.65) 
p=4e-2 
0.11 (-0.25,  0.47) 
p=5e-01 
-0.18 (-0.55, 0.19) 
p=4e-01 
0.67 (0.26, 1.08) 
p=2e-03 
Weighted Median 0.42 (0.21, 0.64) 
p=1e-04 
0.23 (0.00, 0.45) 
p=5e-02 
-0.02 (-0.27, 0.23) 
p=9e-01 
0.56 (0.32, 0.79) 
p=3e-06 
Weighted MBE 0.32 (0.05, 0.59) 
p=2e-02 
0.09 (-0.19, 0.37) 
p=5e-01 
-0.25 (-0.51, 0.02) 
p=7e-02 
0.85 (0.53, 1.17) 
p=4e-06 
52 SNPs (removing outlier SNP rs1011685) 
IVW 0.65 (0.49, 0.80) 
p=4e-11 
0.52 (0.37, 0.68) 
p=1e-08 
0.41 (0.26, 0.57) 
p=2e-06 
0.36 (0.19, 0.53) 
p=8e-05 
MR-Egger     
 Standard 
approach 
0.52 (0.05, 0.99) 
p=3e-02 
I2=0.81 
0.31 (-0.18, 0.79) 
p=2e-01 
I2=0.81 
0.24 (-0.25, 0.72) 
p=3e-01 
I2=0.81 
0.02 (-0.49, 0.52) 
p=9e-01 
I2=0.82 
 SIMEX 
adjusted 
0.60 (-0.02, 1.21) 
p=6e-02 
0.35 (-0.35, 1.05) 
p=3e-01 
0.27 (-0.45,  0.98) 
p=5e-01 
0.02 (-0.71, 0.75) 
p=9e-01 
Weighted Median 0.64 (0.39, 0.88) 
p=4e-07 
0.56 (0.32, 0.80) 
p=5e-06 
0.43 (0.17, 0.69) 
p=1e-03 
0.45 (0.21, 0.69) 
p=3e-04 
Weighted MBE 1.08 (0.29, 1.86) 
p=9e-03 
0.90 ( 0.17, 1.62) 
p=2e-02 
0.84 (-0.17, 1.85) 
p=1e-01 
0.46 (-0.19, 1.10) 
p=2e-01 
28 SNPs (not previously associated HDL-C or TGs at genome-wide significance) 
IVW 0.74 (0.48, 1.01) 
p=4e-06 
0.65 (0.39, 0.92) 
p=3e-05 
0.49 (0.23, 0.75) 
p=7e-04 
0.25 (-0.04, 0.54) 
9e-02 
MR-Egger     
 Standard 
approach 
0.70 (-0.44, 1.83) 
p=2e-01 
I2=0.10 
1.16 (0.04, 2.27) 
p=4e-2 
I2=0.09 
0.62 (-0.53, 1.77) 
p=3e-01 
I2=0.10 
0.30 (-1.03, 1.63) 
p=7e-01 
I2=0.12 
 SIMEX 
adjusted 
1.01 (-0.54,  2.57) 
p=2e-01 
1.63 (0.00, 3.25) 
p=5e-02 
0.86 (-1.03,  2.74) 
p=4e-01 
0.44 (-1.63,  2.51) 
p=7e-01 
Weighted Median 0.92 (0.56, 1.29) 
p=6e-07 
0.77 (0.39, 1.15) 
p=8e-05 
0.55 (0.16, 0.94) 
p=6e-03 
0.42 (0.05, 0.80) 
p=3e-02 
Weighted MBE  1.08 (0.15, 2.00) 
p=3e-02 
0.06 (-0.90, 1.02) 
p=9e-01 
-0.28 (-1.50, 0.93) 
p=7e-01 
0.50 (-0.44,1.44) 
p=3e-01 
 
The results were broadly consistent after removing the outlier SNP (rs1011685). MR-Egger (3) 
suggests there is little directional pleiotropy, as the intercepts were of generally small magnitudes 
(MR-Egger intercepts ≤ 0.01) in comparison with the betas. As MR-Egger estimate of causal effect is 
prone to be underestimated when the assumption of no-measurement error (NOME) is violated, the 
heterogeneity index (I2) was used to detect the extent of the violation and SIMEX-method was used to 
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correct such violation (6). The lower value of I2 (value lies between 0 and 1) indicates stronger NOME 
violation and thus stronger dilution of the estimates. For mode-based estimator (5), the smoothing 
parameter for the empirical density function was set to 0.5, in order to increase the precision to detect 
potential pleiotropy. Weighted median estimates are valid as long as the majority of weights 
contributing to the analyses are valid (4). For all the methods, inverse-variance of the ratio estimators 
were used as the weights. IVW: inverse-variance weighted; GlycA: glycoprotein acetyls. 
 
 
 
 
Supplemental Table 9. The intercepts for MR-Egger. 
 
 Egger-Intercepts SE P value 
53 SNPs 
Ile 0.0061 0.003 0.08 
Leu 0.008 0.004 0.04 
Val 0.0109 0.004 0.01 
GlycA -0.0039 0.004 0.37 
52 SNPs 
Ile 0.0027 0.005 0.62 
Leu 0.0043 0.006 0.48 
Val 0.0036 0.006 0.57 
GlycA 0.0071 0.006 0.26 
28 SNPs 
Ile 0.0008 0.009 0.93 
Leu -0.0083 0.01 0.41 
Val -0.0022 0.012 0.85 
GlycA -0.0008 0.013 0.95 
 
The intercepts of MR Egger were of generally small magnitudes (intercepts ≤ 0.01, far less than the 
betas) with little significance level, suggesting that there is little directional pleiotropy of the genetic 
instruments. 
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Supplemental Table 10. Details of Mendelian randomization studies and estimates to accompany Figure 4. 
Ref in Figure 4 Exposure Outcome Mendelian randomization estimate (per-1SD higher exposure) References 
1 BMI 
Fasting insulin 
HDL-cholesterol 
Triglycerides 
logFI: 0.39 SD (0.29, 0.49); 
HDL-C: -0.22 SD (-0.29, -0.14); 
logTG: 0.19 SD (0.12, 0.28). 
Holmes et al. (9) and Dale et 
al.*(10) 
2 WHRadjBMI 
Fasting insulin 
HDL-cholesterol 
Triglycerides 
logFI: 0.33 SD (0.15, 0.51); 
HDL-C: -0.38 SD (-0.49, -0.28); 
logTG: 0.45 SD (0.28, 0.62). 
Dale et al.* (10) and 
Emdin et al.(11) 
3 BMI BCAAs 
Isoleucine: 0.20 SD (0.12, 0.28); 
Leucine: 0.17 SD (0.09, 0.25); 
Valine: 0.19 SD (0.10, 0.27). 
Würtz et al. (12) and 
Supplemental Figure 3* 
4 WHRadjBMI BCAAs 
Isoleucine: 0.21 SD (0.09, 0.33); 
Leucine: 0.15 SD (0.03, 0.27); 
Valine: 0.10 SD (-0.02, 0.22). 
Supplemental Figure 4 
5 BMI T2D OR 1.96 (1.41, 2.78) 
Holmes et al. (9); Dale et al. *(10); 
Lyall et al. (13) 
6 WHRadjBMI T2D OR 1.82 (1.38, 2.42) Emdin et al. (11); Dale et al.*(10) 
7 Insulin resistance# BCAAs 
Isoleucine: 0.56SD (0.43, 0.70); 
Leucine: 0.42SD (0.28, 0.55); 
Valine: 0.26SD (0.12, 0.39) 
Figure 2*, Mahendran et al. (14) 
8 BCAAs T2D The study provided genetic evidence for a causal link between 
BCAA metabolism and risk of T2D. For further details see ref (15) 
Lotta et al. (16) 
Where more than one reference is provided, the reference followed by * is the one used for the data reported under the “MR 
estimate” column. #: Insulin resistance is a composite trait proxied by higher fasting insulin (adjusted for BMI), triglycerides and 
lower HDL-cholesterol. logFI: logarithm of fasting insulin; SD: standard deviation 
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Supplemental Figure 1. The associations of the individual SNPs for the composite insulin resistance with the individual 
insulin resistance phenotypes. 
 
The SNP associations with insulin (BMI adjusted) was obtained from MAGIC Consortium (8). The SNP associations with TG and 
HDL-C were obtained from GLGC consortium (17). The SNP association with composite insulin resistance was defined as the 
meta-analyzed results of SNP associations with fasting insulin (BMI adjusted), TG and HDL-C. Among the 53 SNPs, most of the 
SNPs fell in a straight line (with a slope equal to 1), suggesting a similar contribution of the three traits to the ‘composite’ insulin 
resistance phenotype with the exception of rs1011685 (near LPL), which had a much weaker effect on insulin adjusted for BMI. 
Each dot indicates one SNP. The horizontal lines denotes the CIs for the associations of SNPs with composite insulin resistance 
while the vertical lines denotes the CIs for the associations of SNPs with the individual phenotypes. 
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Supplemental Figure 2. Causal effect estimates of fasting insulin on circulating 
metabolic measures. 
 
 
Black diamond: Causal effect estimates of insulin resistance (a composite trait 
denoted as increased insulin adjusted for BMI, increased TGs and decreased HDL-
C) on circulating metabolic measures, using insulin resistance associated 53 SNPs 
as the instrument. The unit is SD difference in metabolite concentration per SD 
higher insulin resistance. These are also shown in Figure 2. Grey circle: Causal 
effect estimates of fasting insulin (adjusted for BMI) on the circulating metabolic 
measures, using the 12 loci reported by a previous GWAS as the instrument (8). The 
unit is SD difference in metabolite concentration per SD higher fasting insulin 
(adjusted for BMI). Both estimates were calculated via two-sample Mendelian 
randomization analysis using inverse-variance weighted method (2). 
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Supplemental Figure 3. Causal effect estimates of body mass index on 
branched-chain amino acids and glycoprotein acetyls. 
 
BMI  Amino acids and glycoprotein acetyls 
 
 
The 97 BMI-associated loci reported by previous GWA study (GIANT consortium) were used 
as the instrument to assess the causal effects of BMI on circulating metabolic measures. 
Summary statistics from this BMI-GWAS (up to 322,154 individuals, primarily European) (7) 
and metabolic-GWAS (up to 24,925 participants, European) (18) were used in the two-
sample Mendelian randomization analysis. The causal effect estimates using 97 SNPs were 
calculated by inverse-variance weighted method (red vertical line), MR-Egger (green line) 
weighted median estimator (WME; blue line) and weighted mode-based estimator (WMBE; 
purple line). The 95% CIs for each method are depicted as the colourful horizontal lines. The 
x-axis shows the causal effect estimates using individual SNP as the instrument. The y-axis 
describes the association strength (beta coefficients) of individual SNPs with BMI 
(rs1885988 was used as the genetic proxy for rs12016871; R2>0.8).  
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Supplemental Figure 4. Causal effect estimates of waist-to-hip ratio on 
branched-chain amino acids and glycoprotein acetyls. 
 
Waist-to-hip ratio (adjusted for BMI)  Amino acids and glycoprotein acetyls 
 
 
The 49 waist-to-hip ratio (WHR, BMI-adjusted)-associated loci reported by previous GWA 
study (GIANT consortium) were used as the instrument to assess the causal effects of WHR 
on circulating metabolic measures. Summary statistics from this WHR-GWAS (up to 224,459 
individuals, almost all were European) (19) and metabolic-GWAS (up to 24,925 participants, 
European) (18) were used in the two-sample Mendelian randomization analysis. The causal 
effect estimates using 49 SNPs were calculated by inverse-variance weighted method (red 
vertical line), MR-Egger (green line), weighted median estimator (WME; blue line) and 
weighted mode-based estimator (WMBE; purple line). The x-axis shows the causal effect 
estimates using individual SNPs as the instrument. The y-axis describes the association 
strength (beta coefficients) of individual SNP with WHR. SNP rs7759742 was missing from 
the metabolic-GWAS and was therefore not included in the analysis.
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